GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Forward PE Ratio

Zealand Pharma A/S (Zealand Pharma A/S) Forward PE Ratio : 0.00 (As of May. 22, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Forward PE Ratio?

Zealand Pharma A/S's Forward PE Ratio for today is 0.00.

Zealand Pharma A/S's PE Ratio without NRI for today is 0.00.

Zealand Pharma A/S's PE Ratio for today is 0.00.


Zealand Pharma A/S Forward PE Ratio Historical Data

The historical data trend for Zealand Pharma A/S's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Forward PE Ratio Chart

Zealand Pharma A/S Annual Data
Trend
Forward PE Ratio

Zealand Pharma A/S Quarterly Data
Forward PE Ratio

Competitive Comparison of Zealand Pharma A/S's Forward PE Ratio

For the Biotechnology subindustry, Zealand Pharma A/S's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Forward PE Ratio falls into.



Zealand Pharma A/S Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Zealand Pharma A/S  (OTCPK:ZLDPF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Zealand Pharma A/S Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (Zealand Pharma A/S) Headlines